Amphastar Pharmaceuticals, Inc.
http://www.amphastar.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amphastar Pharmaceuticals, Inc.
US Aspart Filing Kicks Off Amphastar’s Insulin Ambitions
Amphastar says a “milestone” submission of a US filing for insulin aspart underlines its ambitions in the diabetes segment. But could the firm get the first US biosimilar approval?
‘Incremental’ Benefit Of Lumicell’s Cancer Imaging Drug Outweighs Manageable Risk, FDA Panel Says
Most advisory committee members supported approval of the breast cancer imaging product, but indicated labeling and advertising should be carefully crafted to avoid overhyping the likelihood patients experience a clinical benefit.
Lumicell’s Cancer Imaging Drug Faces Clinical Meaningfulness, Anaphylaxis Risk Questions At FDA Panel
US FDA advisory committee briefing documents say drug-device combo Lumisight (pegulicianine) is effective at picking up cancer but it is not clear whether that translates to patient benefit.
News We're Watching: Accenture Expects 'More Human' Tech, Cardiac Genetic Tests In Walmart; And More
Medtech Insight's News We're Watching highlights a few noteworthy industry developments you might have missed: Accenture's new Vision Report addresses the future of "more human" tech in health care; Efemoral secures FDA's breakthrough status for its bioresorbable peripheral stent; Impulse Dynamics secures $135m to support its cardiac contractility modulation; PrecisionLife and Metrodora announced a partnership to address chronic diseases including long COVID; Cardio Diagnostics launches its cardiac epigenetic/genetic tests in a Walmart near Chicago.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- OTC, Consumer
- Specialty Pharmaceuticals
-
Drug Delivery
- Nasal
- Pulmonary
- Other Names / Subsidiaries
-
- Amphastar France Pharmaceuticals (AFP)
- Armstrong Pharmaceuticals, Inc.
- International Medication Systems (IMS)
- Nanjing Puyan Pharmaceutical Technology (ANP)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice